Publications of Susanne B Haga    :chronological  alphabetical  combined  bibtex listing:

We've launched a new site so please go to People & Research for current information on our faculty and staff.

Books

  1. Haga, SB. The book of genes and genomes. January, 2022. 1-236 pp. [doi]  [abs]

Journal Articles

  1. Haga, SB. "The Critical Role of Pharmacists in the Clinical Delivery of Pharmacogenetics in the U.S.." Pharmacy (Basel) 11.5 (September, 2023): 144-144. [doi]  [abs]
  2. Haga, SB; Orlando, LA. "Expanding Family Health History to Include Family Medication History.." J Pers Med 13.3 (February, 2023): 410. [doi]  [abs]
  3. Haga, SB; Chung, WK; Cubano, LA; Curry, TB; Empey, PE; Ginsburg, GS; Mangold, K; Miyake, CY; Prakash, SK; Ramsey, LB; Rowley, R; Rohrer Vitek, CR; Skaar, TC; Wynn, J; Manolio, TA. "Development of Competency-based Online Genomic Medicine Training (COGENT).." Per Med 20.1 (January, 2023): 55-64. [doi]  [abs]
  4. Haga, SB. "Conference Report: NHGRI Research Training and Career Development Annual Meeting.." Per Med (October, 2022). [doi]  [abs]
  5. Sperber, NR; Cragun, D; Roberts, MC; Bendz, LM; Ince, P; Gonzales, S; Haga, SB; Wu, RR; Petry, NJ; Ramsey, L; Uber, R. "A Mixed-Methods Protocol to Identify Best Practices for Implementing Pharmacogenetic Testing in Clinical Settings.." J Pers Med 12.8 (August, 2022). [doi]  [abs]
  6. Bond, SJ; Parikh, N; Majmudar, S; Pin, S; Wang, C; Willis, L; Haga, SB. "A Systematic Review of the Scope of Study of mHealth Interventions for Wellness and Related Challenges in Pediatric and Young Adult Populations.." Adolesc Health Med Ther 13 (2022): 23-38. [doi]  [abs]
  7. Sharma, Y; Cox, L; Kruger, L; Channamsetty, V; Haga, SB. "Evaluating Primary Care Providers' Readiness for Delivering Genetic and Genomic Services to Underserved Populations.." Public health genomics (September, 2021): 1-10. [doi]  [abs]
  8. Kantor, A; Haga, SB. "The Potential Benefit of Expedited Development and Approval Programs in Precision Medicine.." J Pers Med 11.1 (January, 2021): 45. [doi]  [abs]
  9. Haga, SB. "Revisiting Secondary Information Related to Pharmacogenetic Testing.." Frontiers in genetics 12 (January, 2021): 741395. [doi]  [abs]
  10. Haga, SB; Mills, R; Moaddeb, J; Liu, Y; Voora, D. "Delivery of Pharmacogenetic Testing with or without Medication Therapy Management in a Community Pharmacy Setting.." Pharmacogenomics and personalized medicine 14 (January, 2021): 785-796. [doi]  [abs]
  11. Haga, SB; Mills, R; Moaddeb, J; Liu, Y; Voora, D. "Independent Community Pharmacists' Experience in Offering Pharmacogenetic Testing.." Pharmgenomics Pers Med 14 (2021): 877-886. [doi]  [abs]
  12. Haga, SB. "Individualizing pharmacogenomic test results in the context of the microbiome.." Per Med 17.6 (November, 2020): 459-468. [doi]  [abs]
  13. Brown, L; Eum, S; Haga, SB; Strawn, JR; Zierhut, H. "Clinical Utilization of Pharmacogenetics in Psychiatry - Perspectives of Pharmacists, Genetic Counselors, Implementation Science, Clinicians, and Industry.." Pharmacopsychiatry 53.4 (July, 2020): 162-173. [doi]  [abs]
  14. Haga, SB. "Toward digital-based interventions for medication adherence and safety.." Expert Opin Drug Saf 19.6 (June, 2020): 735-746. [doi]  [abs]
  15. Haga, SB; Orlando, LA. "The enduring importance of family health history in the era of genomic medicine and risk assessment.." Per Med 17.3 (May, 2020): 229-239. [doi]  [abs]
  16. Haga, SB; Shaw, R; Kneifel, C; Bond, SJ; Ginsburg, GS. "Promoting Wellness Through Mobile Health Technology in a College Student Population: Protocol Development and Pilot Study.." JMIR Res Protoc 9.4 (April, 2020): e16474. [doi]  [abs]
  17. Phillips, K; Haga, S. "Precision Medicine in Primary Care: Bespoke. Genetic and Genomic. And Maybe Not Ready." Managed Care 28.12 (December, 2019): 30-33.  [abs]
  18. Haga, SB. "Managing Increased Accessibility to Pharmacogenomic Data.." Clin Pharmacol Ther 106.5 (November, 2019): 922-924. [doi]
  19. Haga, SB; Shaw, R; Kneifel, C; Bond, SJ; Ginsburg, GS. "Promoting Wellness Through Mobile Health Technology in a College Student Population: Protocol Development and Pilot Study (Preprint)." (October, 2019). [doi]  [abs]
  20. Weitzel, KW; Duong, BQ; Arwood, MJ; Owusu-Obeng, A; Abul-Husn, NS; Bernhardt, BA; Decker, B; Denny, JC; Dietrich, E; Gums, J; Madden, EB; Pollin, TI; Wu, RR; Haga, SB; Horowitz, CR. "A stepwise approach to implementing pharmacogenetic testing in the primary care setting.." Pharmacogenomics 20.15 (October, 2019): 1103-1112. [doi]  [abs]
  21. Haga, SB. "First Responder to Genomic Information: A Guide for Primary Care Providers.." Mol Diagn Ther 23.4 (August, 2019): 459-466. [doi]  [abs]
  22. Villegas, C; Haga, SB. "Access to Genetic Counselors in the Southern United States.." J Pers Med 9.3 (July, 2019): E33. [doi]  [abs]
  23. Haga, SB; Liu, Y. "Patient characteristics, experiences and perceived value of pharmacogenetic testing from a single testing laboratory.." Pharmacogenomics 20.8 (June, 2019): 581-587. [doi]  [abs]
  24. Haga, SB; Moaddeb, J. "Pharmacogenomics courses in pharmacy school curricula.." Pharmacogenomics 20.9 (June, 2019): 625-630. [doi]  [abs]
  25. Haga, SB; Kim, E; Myers, RA; Ginsburg, GS. "Primary Care Physicians' Knowledge, Attitudes, and Experience with Personal Genetic Testing.." J Pers Med 9.2 (May, 2019). [doi]  [abs]
  26. Wu, RR; Myers, RA; Buchanan, AH; Dimmock, D; Fulda, KG; Haller, IV; Haga, SB; Harry, ML; McCarty, C; Neuner, J; Rakhra-Burris, T; Sperber, N; Voils, CI; Ginsburg, GS; Orlando, LA. "Effect of Sociodemographic Factors on Uptake of a Patient-Facing Information Technology Family Health History Risk Assessment Platform.." Appl Clin Inform 10.2 (March, 2019): 180-188. [doi]  [abs]
  27. Haga, SB. "Pharmacogenomic Testing In Pediatrics: Navigating The Ethical, Social, And Legal Challenges.." Pharmgenomics Pers Med 12 (2019): 273-285. [doi]  [abs]
  28. Madhavan, S; Bullis, E; Myers, R; Zhou, CJ; Cai, EM; Sharma, A; Bhatia, S; Orlando, LA; Haga, SB. "Awareness of family health history in a predominantly young adult population.." PLoS One 14.10 (2019): e0224283. [doi]  [abs]
  29. Peyser, B; Perry, EP; Singh, K; Gill, RD; Mehan, MR; Haga, SB; Musty, MD; Milazzo, NA; Savard, D; Li, Y-J; Trujilio, G; Voora, D. "Effects of Delivering SLCO1B1 Pharmacogenetic Information in Randomized Trial and Observational Settings.." Circ Genom Precis Med 11.9 (September, 2018): e002228. [doi]  [abs]
  30. Haga, SB; Kantor, A. "Horizon Scan Of Clinical Laboratories Offering Pharmacogenetic Testing.." Health Aff (Millwood) 37.5 (May, 2018): 717-723. [doi]  [abs]
  31. Mills, R; Haga, SB. "Qualitative user evaluation of a revised pharmacogenetic educational toolkit.." Pharmgenomics Pers Med 11 (2018): 139-146. [doi]  [abs]
  32. Haga, SB; Friedman, B; Richard, G. "Considering the Benefits and Risks of Research Participants' Access to Sequence Data.." Genet Test Mol Biomarkers 21.12 (December, 2017): 717-721. [doi]  [abs]
  33. Huddleston, KL; Klein, E; Fuller, A; Jo, G; Lawrence, G; Haga, SB. "Introducing personalized health for the family: the experience of a single hospital system.." Pharmacogenomics 18.17 (November, 2017): 1589-1594. [doi]  [abs]
  34. Haga, SB. "Informational Quest.." Circ Cardiovasc Genet 10.4 (August, 2017). [doi]
  35. Haga, SB. "Educating patients and providers through comprehensive pharmacogenetic test reports.." Pharmacogenomics 18.11 (July, 2017): 1047-1050. [doi]
  36. Mills, R; Ensinger, M; Callanan, N; Haga, SB. "Development and Initial Assessment of a Patient Education Video about Pharmacogenetics.." J Pers Med 7.2 (May, 2017). [doi]  [abs]
  37. Haga, SB; Mills, R; Moaddeb, J; Allen LaPointe, N; Cho, A; Ginsburg, GS. "Primary care providers' use of pharmacist support for delivery of pharmacogenetic testing.." Pharmacogenomics 18.4 (March, 2017): 359-367. [doi]  [abs]
  38. Haga, SB. "Update: looking beyond the 100,000 Genome Project.." Per Med 14.2 (March, 2017): 85-87. [doi]
  39. Haga, SB; Moaddeb, J; Mills, R; Voora, D. "Assessing feasibility of delivering pharmacogenetic testing in a community pharmacy setting.." Pharmacogenomics 18.4 (March, 2017): 327-335. [doi]  [abs]
  40. Haga, SB. "Integrating pharmacogenetic testing into primary care.." Expert Rev Precis Med Drug Dev 2.6 (2017): 327-336. [doi]  [abs]
  41. Singh, K; Peyser, B; Trujillo, G; Milazzo, N; Savard, D; Haga, SB; Musty, M; Voora, D. "Rationale and design of the SLCO1B1 genotype guided statin therapy trial.." Pharmacogenomics 17.17 (November, 2016): 1873-1880. [doi]
  42. Haga, SB; Mills, R; Moaddeb, J; Allen Lapointe, N; Cho, A; Ginsburg, GS. "Patient experiences with pharmacogenetic testing in a primary care setting.." Pharmacogenomics 17.15 (October, 2016): 1629-1636. [doi]  [abs]
  43. Haga, SB; Mills, R; Moaddeb, J. "Evaluation of a pharmacogenetic educational toolkit for community pharmacists.." Pharmacogenomics 17.14 (September, 2016): 1491-1502. [doi]  [abs]
  44. Haga, SB; Mills, R. "A review of consent practices and perspectives for pharmacogenetic testing.." Pharmacogenomics 17.14 (September, 2016): 1595-1605. [doi]  [abs]
  45. Haga, SB. "Challenges of development and implementation of point of care pharmacogenetic testing.." Expert Rev Mol Diagn 16.9 (September, 2016): 949-960. [doi]  [abs]
  46. Haga, SB; Solomon, BD. "Considerations of pharmacogenetic testing in children.." Pharmacogenomics 17.9 (June, 2016): 975-977. [doi]
  47. Arora, S; Haverfield, E; Richard, G; Haga, SB; Mills, R. "Clinical and Counseling Experiences of Early Adopters of Whole Exome Sequencing.." J Genet Couns 25.2 (April, 2016): 337-343. [doi]  [abs]
  48. Haga, SB; Moaddeb, J. "Proposal for a pharmacogenetics certificate program for pharmacists.." Pharmacogenomics 17.6 (April, 2016): 535-539. [doi]
  49. Haga, SB; Moaddeb, J; Mills, R; Patel, M; Kraus, W; Allen LaPointe, NM. "Incorporation of pharmacogenetic testing into medication therapy management.." Pharmacogenomics 16.17 (November, 2015): 1931-1941. [doi]  [abs]
  50. Haga, SB; Mills, R; Aucoin, J; Taekman, J. "Interprofessional education for personalized medicine through technology-based learning.." Per Med 12.3 (June, 2015): 237-243. [doi]  [abs]
  51. Haga, SB; Allen LaPointe, NM; Moaddeb, J. "Challenges to integrating pharmacogenetic testing into medication therapy management.." J Manag Care Spec Pharm 21.4 (April, 2015): 346-352. [doi]  [abs]
  52. Mills, R; Powell, J; Barry, W; Haga, SB. "Information-seeking and sharing behavior following genomic testing for diabetes risk.." J Genet Couns 24.1 (February, 2015): 58-66. [doi]  [abs]
  53. Deverka, PA; Haga, SB. "Comparative effectiveness research and demonstrating clinical utility for molecular diagnostic tests.." Clin Chem 61.1 (January, 2015): 142-144. [doi]
  54. Gallagher, P; King, HA; Haga, SB; Orlando, LA; Joy, SV; Trujillo, GM; Scott, WM; Bembe, M; Creighton, DL; Cho, AH; Ginsburg, GS; Vorderstrasse, A. "Patient beliefs and behaviors about genomic risk for type 2 diabetes: implications for prevention.." J Health Commun 20.6 (2015): 728-735. [doi]  [abs]
  55. Haga, SB; Mills, R. "Nurses' communication of pharmacogenetic test results as part of discharge care.." Pharmacogenomics 16.3 (2015): 251-256. [doi]  [abs]
  56. Moaddeb, J; Mills, R; Haga, SB. "Community pharmacists' experience with pharmacogenetic testing.." J Am Pharm Assoc (2003) 55.6 (2015): 587-594. [doi]  [abs]
  57. Haga, SB; Moaddeb, J. "Potential use of auxiliary labels to promote patient awareness of pharmacogenetic testing.." Pharmacogenomics 16.4 (2015): 299-301. [doi]
  58. Haga, SB; Allen LaPointe, NM; Moaddeb, J; Mills, R; Patel, M; Kraus, WE. "Pilot study: incorporation of pharmacogenetic testing in medication therapy management services.." Pharmacogenomics 15.14 (November, 2014): 1729-1737. [doi]  [abs]
  59. Haga, SB; Mills, R; Bosworth, H. "Striking a balance in communicating pharmacogenetic test results: promoting comprehension and minimizing adverse psychological and behavioral response.." Patient Educ Couns 97.1 (October, 2014): 10-15. [doi]  [abs]
  60. Haga, SB; LaPointe, NMA; Cho, A; Reed, SD; Mills, R; Moaddeb, J; Ginsburg, GS. "Pilot study of pharmacist-assisted delivery of pharmacogenetic testing in a primary care setting.." Pharmacogenomics 15.13 (September, 2014): 1677-1686. [doi]  [abs]
  61. Mills, R; Haga, SB. "Genomic counseling: next generation counseling.." J Genet Couns 23.4 (August, 2014): 689-692. [24026254], [doi]  [abs]
  62. Mills, R; Barry, W; Haga, SB. "Public trust in genomic risk assessment for type 2 diabetes mellitus.." J Genet Couns 23.3 (June, 2014): 401-408. [doi]  [abs]
  63. Li, JH; Joy, SV; Haga, SB; Orlando, LA; Kraus, WE; Ginsburg, GS; Voora, D. "Genetically guided statin therapy on statin perceptions, adherence, and cholesterol lowering: a pilot implementation study in primary care patients.." J Pers Med 4.2 (March, 2014): 147-162. [doi]  [abs]
  64. Haga, SB; Moaddeb, J. "Comparison of delivery strategies for pharmacogenetic testing services.." Pharmacogenet Genomics 24.3 (March, 2014): 139-145. [24384556], [doi]  [abs]
  65. Zhao, JQ; Haga, SB. "Promoting the participant-researcher partnership.." Genet Med 16.3 (March, 2014): 228-230. [24009003], [doi]
  66. Haga, SB. "Delivering pharmacogenetic testing to the masses: an achievable goal?." Pharmacogenomics 15.1 (January, 2014): 1-4. [24329184], [doi]
  67. Haga, SB; Mills, R; Pollak, KI; Rehder, C; Buchanan, AH; Lipkus, IM; Crow, JH; Datto, M. "Developing patient-friendly genetic and genomic test reports: formats to promote patient engagement and understanding.." Genome Med 6.7 (2014): 58. [doi]  [abs]
  68. Haga, SB; Mills, R; Moaddeb, J. "Pharmacogenetic information for patients on drug labels.." Pharmgenomics Pers Med 7 (2014): 297-305. [doi]  [abs]
  69. Haga, SB; Barry, WT; Mills, R; Svetkey, L; Suchindran, S; Willard, HF; Ginsburg, GS. "Impact of delivery models on understanding genomic risk for type 2 diabetes.." Public Health Genomics 17.2 (2014): 95-104. [doi]  [abs]
  70. Haga, SB; LaPointe, NMA. "The potential impact of pharmacogenetic testing on medication adherence.." Pharmacogenomics J 13.6 (December, 2013): 481-483. [23999596], [doi]  [abs]
  71. Haga, SB. "100k Genome Project: sequencing and much more.." Per Med 10.8 (November, 2013): 761-764. [doi]
  72. Clayton, EW; Haga, S; Kuszler, P; Bane, E; Shutske, K; Burke, W. "Managing incidental genomic findings: legal obligations of clinicians.." Genet Med 15.8 (August, 2013): 624-629. [doi]  [abs]
  73. Haga, SB; Rosanbalm, KD; Boles, L; Tindall, GM; Livingston, TM; O'Daniel, JM. "Promoting public awareness and engagement in genome sciences.." J Genet Couns 22.4 (August, 2013): 508-516. [23435715], [doi]  [abs]
  74. Moaddeb, J; Haga, SB. "Pharmacogenetic testing: Current Evidence of Clinical Utility.." Ther Adv Drug Saf 4.4 (August, 2013): 155-169. [24020014], [doi]  [abs]
  75. Haga, SB; Burke, W; Agans, R. "Primary-care physicians' access to genetic specialists: an impediment to the routine use of genomic medicine?." Genet Med 15.7 (July, 2013): 513-514. [23306802], [doi]  [abs]
  76. Mills, R; Haga, SB. "Clinical delivery of pharmacogenetic testing services: a proposed partnership between genetic counselors and pharmacists.." Pharmacogenomics 14.8 (June, 2013): 957-968. [23746189], [doi]  [abs]
  77. Haga, SB; Barry, WT; Mills, R; Ginsburg, GS; Svetkey, L; Sullivan, J; Willard, HF. "Public knowledge of and attitudes toward genetics and genetic testing.." Genet Test Mol Biomarkers 17.4 (April, 2013): 327-335. [23406207], [doi]  [abs]
  78. Haga, SB; Burke, W; Ginsburg, GS; Mills, R; Agans, R. "Primary care physicians' knowledge of and experience with pharmacogenetic testing." Obstetrical and Gynecological Survey 68.2 (February, 2013): 91-93. [doi]
  79. Haga, SB; Zhao, JQ. "Stakeholder views on returning research results.." Adv Genet 84 (2013): 41-81. [24262096], [doi]  [abs]
  80. Mills, R; Voora, D; Peyser, B; Haga, SB. "Delivering pharmacogenetic testing in a primary care setting.." Pharmgenomics Pers Med 6 (2013): 105-112. [24101877], [doi]  [abs]
  81. Hresko, A; Haga, SB. "Insurance coverage policies for personalized medicine.." J Pers Med 2.4 (October, 2012): 201-216. [doi]  [abs]
  82. Haga, SB; Burke, W; Ginsburg, GS; Mills, R; Agans, R. "Primary care physicians' knowledge of and experience with pharmacogenetic testing.." Clin Genet 82.4 (October, 2012): 388-394. [22698141], [doi]  [abs]
  83. Mills, RA; Haga, SB; Ginsburg, GS. "Genetic testing: clinical and personal utility.." Virtual Mentor 14.8 (August, 2012): 604-609. [23351313], [doi]
  84. Haga, SB; O'Daniel, JM; Tindall, GM; Mills, R; Lipkus, IM; Agans, R. "Survey of genetic counselors and clinical geneticists' use and attitudes toward pharmacogenetic testing.." Clin Genet 82.2 (August, 2012): 115-120. [22283474], [doi]  [abs]
  85. Haga, SB; O'Daniel, JM; Tindall, GM; Mills, R; Lipkus, I; Agans, R. "Response to Newman et al." Clinical Genetics 82.2 (August, 2012): 203. [doi]
  86. Kraus, WE; Haga, SB; McLeod, HL; Staples, J; Ginsburg, GS. "Conference Scene: Is personalized medicine ready for prime time?." Per Med 9.5 (July, 2012): 475-478. [doi]  [abs]
  87. Haga, SB; O'Daniel, JM; Tindall, GM; Lipkus, IR; Agans, R. "Survey of US public attitudes toward pharmacogenetic testing.." Pharmacogenomics J 12.3 (June, 2012): 197-204. [21321582], [doi]  [abs]
  88. Haga, SB; Tindall, G; O'Daniel, JM. "Public perspectives about pharmacogenetic testing and managing ancillary findings.." Genet Test Mol Biomarkers 16.3 (March, 2012): 193-197. [22047505], [doi]  [abs]
  89. O'Daniel, JM; Rosanbalm, KD; Boles, L; Tindall, GM; Livingston, TM; Haga, SB. "Enhancing geneticists' perspectives of the public through community engagement.." Genet Med 14.2 (February, 2012): 243-249. [22241095], [doi]  [abs]
  90. Cho, AH; Killeya-Jones, LA; O'Daniel, JM; Kawamoto, K; Gallagher, P; Haga, S; Lucas, JE; Trujillo, GM; Joy, SV; Ginsburg, GS. "Effect of genetic testing for risk of type 2 diabetes mellitus on health behaviors and outcomes: study rationale, development and design.." BMC Health Serv Res 12 (January, 2012): 16. [22257365], [doi]  [abs]
  91. Haga, SB; Tindall, G; O'Daniel, JM. "Professional perspectives about pharmacogenetic testing and managing ancillary findings.." Genet Test Mol Biomarkers 16.1 (January, 2012): 21-24. [21770772], [doi]  [abs]
  92. Kanakamedala, P; Haga, SB. "Characterization of clinical study populations by race and ethnicity in biomedical literature.." Ethn Dis 22.1 (2012): 96-101. [22774316]  [abs]
  93. Haga, SB; Kawamoto, K; Agans, R; Ginsburg, GS. "Consideration of patient preferences and challenges in storage and access of pharmacogenetic test results.." Genet Med 13.10 (October, 2011): 887-890. [21673581], [doi]  [abs]
  94. Haga, SB; O'Daniel, JM; Tindall, GM; Lipkus, IR; Agans, R. "Public attitudes toward ancillary information revealed by pharmacogenetic testing under limited information conditions.." Genet Med 13.8 (August, 2011): 723-728. [21633294], [doi]  [abs]
  95. Haga, SB; Carrig, MM; O'Daniel, JM; Orlando, LA; Killeya-Jones, LA; Ginsburg, GS; Cho, A. "Genomic risk profiling: attitudes and use in personal and clinical care of primary care physicians who offer risk profiling.." J Gen Intern Med 26.8 (August, 2011): 834-840. [21311998], [doi]  [abs]
  96. Haga, SB; Burke, W. "Practical ethics: establishing a pathway to benefit for complex pharmacogenomic tests.." Clin Pharmacol Ther 90.1 (July, 2011): 25-27. [21691271], [doi]  [abs]
  97. Haga, SB; O'Daniel, J. "Public perspectives regarding data-sharing practices in genomics research.." Public Health Genomics 14.6 (2011): 319-324. [21430368], [doi]  [abs]
  98. O'Daniel, J; Haga, SB. "Public perspectives on returning genetics and genomics research results.." Public Health Genomics 14.6 (2011): 346-355. [21555865], [doi]  [abs]
  99. Heaney, C; Tindall, G; Lucas, J; Haga, SB. "Researcher practices on returning genetic research results.." Genet Test Mol Biomarkers 14.6 (December, 2010): 821-827. [20939736], [doi]  [abs]
  100. Surh, LC; Pacanowski, MA; Haga, SB; Hobbs, S; Lesko, LJ; Gottlieb, S; Papaluca-Amati, M; Patterson, SD; Hughes, AR; Kim, M-J; Close, SL; Mosteller, M; Zineh, I; Dechairo, B; Cohen, NA. "Learning from product labels and label changes: how to build pharmacogenomics into drug-development programs.." Pharmacogenomics 11.12 (December, 2010): 1637-1647. [doi]  [abs]
  101. Haga, SB. "Analysis of educational materials and destruction/opt-out initiatives for storage and use of residual newborn screening samples.." Genet Test Mol Biomarkers 14.5 (October, 2010): 587-592. [20858049], [doi]  [abs]
  102. O'Daniel, JM; Haga, SB; Willard, HF. "Considerations for the impact of personal genome information: a study of genomic profiling among genetics and genomics professionals.." J Genet Couns 19.4 (August, 2010): 387-401. [20352309], [doi]  [abs]
  103. Haga, SB. "Impact of limited population diversity of genome-wide association studies.." Genet Med 12.2 (February, 2010): 81-84. [20057316], [doi]  [abs]
  104. O'Daniel, J; Lucas, J; Deverka, P; Ermentrout, D; Silvey, G; Lobach, DF; Haga, SB. "Factors influencing uptake of pharmacogenetic testing in a diverse patient population.." Public Health Genomics 13.1 (2010): 48-54. [19407441], [doi]  [abs]
  105. Haga, SB; Terry, SF. "Ensuring the safe use of genomic medicine in children.." Clin Pediatr (Phila) 48.7 (September, 2009): 703-708. [19448129], [doi]  [abs]
  106. Haga, SB. "Ethical issues of predictive genetic testing for diabetes.." Journal of diabetes science and technology 3.4 (July, 2009): 781-788. [20144329], [doi]  [abs]
  107. Haga, SB; Warner, LR; O'Daniel, J. "The potential of a placebo/nocebo effect in pharmacogenetics.." Public Health Genomics 12.3 (2009): 158-162. [19204418], [doi]  [abs]
  108. Haga, SB; Burke, W. "Pharmacogenetic testing: not as simple as it seems.." Genet Med 10.6 (June, 2008): 391-395. [18496219], [doi]  [abs]
  109. Haga, SB; Willard, HF. "Letting the genome out of the bottle.." N Engl J Med 358.20 (May, 2008): 2184. [doi]
  110. Haga, SB; Beskow, LM. "Ethical, legal, and social implications of biobanks for genetics research.." Adv Genet 60 (2008): 505-544. [18358331], [doi]  [abs]
  111. Silvey, GM; Haga, SB; O'Daniel, JM; Deverka, P; Ermentrout, DM; Anstrom, KJ; Lobach, DF. "Determining user preferences between touch and pen data entry methods in the Tablet PC computing environment.." AMIA Annu Symp Proc (October, 2007): 1115. [18694212]  [abs]
  112. Haga, SB; Thummel, KE; Burke, W. "Adding pharmacogenetics information to drug labels: lessons learned.." Pharmacogenet Genomics 16.12 (December, 2006): 847-854. [17108808], [doi]  [abs]
  113. Haga, SB; Willard, HF. "Defining the spectrum of genome policy.." Nat Rev Genet 7.12 (December, 2006): 966-972. [17139328], [doi]  [abs]
  114. Haga, SB. "Genomics-based labeling and attribution: a case for integrating social sciences into personalized medicine research.." Per Med 3.3 (August, 2006): 317-323. [doi]  [abs]
  115. Haga, SB; Ginsburg, GS. "Prescribing BiDil: is it black and white?." J Am Coll Cardiol 48.1 (July, 2006): 12-14. [16814642], [doi]  [abs]
  116. Haga, SB. "Teaching resources for genetics.." Nat Rev Genet 7.3 (March, 2006): 223-229. [16462854], [doi]  [abs]
  117. Ginsburg, GS; Haga, SB. "Translating genomic biomarkers into clinically useful diagnostics.." Expert Rev Mol Diagn 6.2 (March, 2006): 179-191. [16512778], [doi]  [abs]
  118. Rich, EC; Burke, W; Heaton, CJ; Haga, S; Pinsky, L; Short, MP; Acheson, L. "Erratum: Reconsidering the family history in primary care (Journal of General Internal Medicine (2004) 19 (273-280))." Journal of General Internal Medicine 20.3 (March, 2005): 315. [doi]
  119. Haga, SB. "Embracing our duty." American Journal of Human Genetics 76.4 (January, 2005): 547. [doi]
  120. Haga, SB; Burke, W. "Using pharmacogenetics to improve drug safety and efficacy.." JAMA 291.23 (June, 2004): 2869-2871. [doi]
  121. Rich, EC; Burke, W; Heaton, CJ; Haga, S; Pinsky, L; Short, MP; Acheson, L. "Reconsidering the family history in primary care.." J Gen Intern Med 19.3 (March, 2004): 273-280. [doi]  [abs]
  122. Haga, SB; Khoury, MJ; Burke, W. "Genomic profiling to promote a healthy lifestyle: not ready for prime time.." Nat Genet 34.4 (August, 2003): 347-350. [doi]  [abs]
  123. Haga, SB; Venter, JC. "Genetics. FDA races in wrong direction.." Science 301.5632 (July, 2003): 466. [doi]  [abs]
  124. Haga, SB; Boughman, JA. "The genetics workforce and workload.." Genet Med 5.1 (2003): 55-57. [doi]
  125. Chase, MB; Fu, S; Haga, SB; Davenport, G; Stevenson, H; Do, K; Morgan, D; Mah, AL; Berg, PE. "BP1, a homeodomain-containing isoform of DLX4, represses the beta-globin gene.." Mol Cell Biol 22.8 (April, 2002): 2505-2514. [doi]  [abs]
  126. Fu, S; Stevenson, H; Strovel, JW; Haga, SB; Stamberg, J; Do, K; Berg, PE. "Distinct functions of two isoforms of a homeobox gene, BP1 and DLX7, in the regulation of the beta-globin gene.." Gene 278.1-2 (October, 2001): 131-139. [doi]  [abs]
  127. Haga, SB; Fu, S; Karp, JE; Ross, DD; Williams, DM; Hankins, WD; Behm, F; Ruscetti, FW; Chang, M; Smith, BD; Becton, D; Raimondi, SC; Berg, PE. "BP1, a new homeobox gene, is frequently expressed in acute leukemias.." Leukemia 14.11 (November, 2000): 1867-1875. [doi]  [abs]
  128. Chase, MB; Haga, SB; Hankins, WD; Williams, DM; Bi, Z; Strovel, JW; Obriecht, C; Berg, PE. "Binding of HMG-I(Y) elicits structural changes in a silencer of the human beta-globin gene.." Am J Hematol 60.1 (January, 1999): 27-35. [doi]  [abs]

Chapters in Books

  1. Haga, SB. "Precision medicine: Overview and challenges to clinical implementation." Principles of Gender-Specific Medicine: Sex and Gender-Specific Biology in the Postgenomic Era. January, 2023: 513-529. [doi]  [abs]
  2. Ginsburg, GS; Haga, SB. "Foundations and application of precision medicine." Emery and Rimoin's Principles and Practice of Medical Genetics and Genomics: Foundations. January, 2018: 21-45. [doi]  [abs]
  3. Haga, SB. "Precision Medicine and Challenges in Research and Clinical Implementation." Principles of Gender-Specific Medicine: Gender in the Genomic Era: Third Edition. Elsevier, May, 2017: 717-732. [doi]  [abs]
  4. Haga, SB. "Overview of Policy, Ethical, and Social Considerations in Genomic and Personalized Medicine." Genomic and Precision Medicine: Primary Care: Third Edition. Elsevier, March, 2017: 19-43. [doi]  [abs]
  5. Haga, SB. "Overview of Policy, Ethical and Social Considerations in Genomic and Personalized Medicine." Genomic and Personalized Medicine. August, 2013: 392-404. [doi]
  6. Cho, A; Vorderstrasse, A; Suchindran, S; Lucas, J; Scott, WM; Bembe, M; Baker, D; Haga, SB; Orlando, L; Trujillo, GM; Joy, SV; Ginsburg, GS. "T2D Genetic Risk Counseling & Testing in Primary Care."  AMER DIABETES ASSOC, July, 2013: A196-A196.
  7. Haga, SB. "Overview of Policy, Ethical and Social Considerations in Genomic and Personalized Medicine." Genomic and Personalized Medicine. November, 2012: 392-404. [doi]
  8. Haga, SB. "Genome Policy Considerations for Genomic Medicine." Essentials of Genomic and Personalized Medicine. Elsevier, December, 2010: 209-222. [doi]  [abs]
  9. Haga, SB. "From Sequence to Genomic Medicine: Genome Policy Considerations." Genomic and Personalized Medicine, Two-Vol Set. Elsevier, December, 2009: 387-400. [doi]
  10. Haga, SB. "From Sequence to Genomic Medicine: Genome Policy Considerations." GENOMIC AND PERSONALIZED MEDICINE, VOL 1. 2009: 388-400.
  11. Haga, SB. "From Sequence to Genomic Medicine: Genome Policy Considerations." Genomic and Personalized Medicine: V1-2. November, 2008: 387-400. [doi]

Susanne B Haga